10x Genomics Q1 2025 10-Q Filed
Ticker: TXG · Form: 10-Q · Filed: May 9, 2025 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue, balance-sheet
TL;DR
**10x Genomics Q1 2025 10-Q is in! Check financials for revenue trends.**
AI Summary
10x Genomics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including product and service revenue and licensing and royalty revenue for the first quarter of 2025 compared to the same period in 2024. It also provides balance sheet information as of March 31, 2025, and December 31, 2024.
Why It Matters
This filing provides investors with the latest financial snapshot of 10x Genomics, crucial for understanding the company's revenue trends and financial health in early 2025.
Risk Assessment
Risk Level: medium — The filing contains standard financial disclosures, but the nature of the life sciences industry and the company's specific market position introduce inherent risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Marks the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Marks the beginning of the financial quarter being reported.)
- 2024-12-31 — Previous Year End Date (Provides a comparison point for balance sheet items.)
Key Players & Entities
- 10x Genomics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250509 (date) — Filing date
FAQ
What was the Product and Service Revenue for Q1 2025?
The filing indicates Product and Service Revenue for the period January 1, 2025 to March 31, 2025, but the specific dollar amount is not detailed in the provided snippet.
How did Licensing and Royalty Revenue in Q1 2025 compare to Q1 2024?
The filing shows data points for Licensing and Royalty Revenue for both Q1 2025 and Q1 2024, suggesting a comparison is available within the full document.
What are the key balance sheet figures as of March 31, 2025?
The filing references Common Stock, Additional Paid In Capital, Retained Earnings, and Accumulated Other Comprehensive Income as of March 31, 2025, with specific values to be found in the full report.
What is the fiscal year end for 10x Genomics, Inc.?
The fiscal year end for 10x Genomics, Inc. is December 31.
What is the SEC file number for 10x Genomics, Inc.?
The SEC file number for 10x Genomics, Inc. is 001-39035.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding 10x Genomics, Inc. (TXG).